Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

FEZ1/LZTS1 protein expression in ovarian cancer.

Califano D, Pignata S, Pisano C, Greggi S, Laurelli G, Losito NS, Ottaiano A, Gallipoli A, Pasquinelli R, De Simone V, Cirombella R, Fusco A, Chiappetta G.

J Cell Physiol. 2010 Feb;222(2):382-6. doi: 10.1002/jcp.21962.

PMID:
19885841
2.

Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.

Beussel S, Hasenburg A, Bogatyreva L, Hauschke D, Werner M, Lassmann S.

J Clin Pathol. 2012 Jan;65(1):29-35. doi: 10.1136/jclinpath-2011-200212. Epub 2011 Oct 19.

PMID:
22011448
3.

Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.

Nonaka D, Fabbri A, Roz L, Mariani L, Vecchione A, Moore GW, Tavecchio L, Croce CM, Sozzi G.

Cancer Res. 2005 Feb 15;65(4):1207-12.

4.

Fez1/lzts1 alterations in gastric carcinoma.

Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM, Baffa R.

Clin Cancer Res. 2001 Jun;7(6):1546-52.

5.

Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C.

Mod Pathol. 2009 Apr;22(4):579-88. doi: 10.1038/modpathol.2009.14. Epub 2009 Mar 6.

6.

FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.

Vecchione A, Ishii H, Baldassarre G, Bassi P, Trapasso F, Alder H, Pagano F, Gomella LG, Croce CM, Baffa R.

Am J Pathol. 2002 Apr;160(4):1345-52.

7.

Expression of beta-tubulin isotypes in human primary ovarian carcinoma.

Ohishi Y, Oda Y, Basaki Y, Kobayashi H, Wake N, Kuwano M, Tsuneyoshi M.

Gynecol Oncol. 2007 Jun;105(3):586-92. Epub 2007 Mar 6.

PMID:
17343904
8.

Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.

Elstrand MB, Kleinberg L, Kohn EC, Tropé CG, Davidson B.

Int J Gynecol Pathol. 2009 May;28(3):211-21. doi: 10.1097/PGP.0b013e31818b0f5e.

PMID:
19620938
9.

p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma.

Hiyoshi Y, Watanabe M, Hirashima K, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Baba H.

Oncol Rep. 2009 Jul;22(1):35-9.

PMID:
19513502
10.

Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.

Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R.

Hum Pathol. 2009 May;40(5):705-13. doi: 10.1016/j.humpath.2008.09.019. Epub 2009 Jan 20.

PMID:
19157507
11.

Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases.

Vecchione A, Galetti TP, Gardiman M, Ishii H, Giarnieri E, Pagano F, Gomella LG, Croce CM, Baffa R.

BMC Urol. 2004 Sep 9;4:11.

12.

FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.

Ishii H, Vecchione A, Murakumo Y, Baldassarre G, Numata S, Trapasso F, Alder H, Baffa R, Croce CM.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10374-9. Epub 2001 Aug 14.

13.
14.

Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study.

Veerman MM, van der Wurff AA, van de Water M, Kruitwagen RF, Feijen HW, Vos MC.

Int J Gynecol Pathol. 2009 Sep;28(5):432-41. doi: 10.1097/PGP.0b013e31819b2864.

PMID:
19696612
15.

Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.

Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, Oie S, Suzuki N, Kono S, Tsuneyoshi M, Ono M, Yanagawa T, Kuwano M.

Clin Cancer Res. 2009 Feb 15;15(4):1473-80. doi: 10.1158/1078-0432.CCR-08-1274.

16.

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.

Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB.

Mod Pathol. 2009 Mar;22(3):393-402. doi: 10.1038/modpathol.2008.191. Epub 2008 Dec 5.

17.

LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.

Yang Y, Yang H, McNutt MA, Xiong F, Nie X, Li L, Zhou R.

Oncol Rep. 2008 Nov;20(5):1077-83.

PMID:
18949404
18.

Expression of 14-3-3sigma in cervical squamous cell carcinomas: relationship with clinical outcome.

Holm R, Ali T, Svendsrud DH, Nesland JM, Kristensen GB, Lyng H.

Oncol Rep. 2009 Jul;22(1):11-5.

PMID:
19513498
19.

Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.

Leffers N, Lambeck AJ, de Graeff P, Bijlsma AY, Daemen T, van der Zee AG, Nijman HW.

Gynecol Oncol. 2008 Sep;110(3):365-73. doi: 10.1016/j.ygyno.2008.04.043. Epub 2008 Jun 20.

PMID:
18571704
20.

Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.

Noske A, Lipka S, Budczies J, Müller K, Loddenkemper C, Buhr HJ, Kruschewski M.

Oncol Rep. 2009 Jul;22(1):3-9.

PMID:
19513497
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk